Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiogenesis patents angiogenic growth factors:

This article was originally published in Clinica

Executive Summary

Cardiogenesis has been granted a patent covering the use of angiogenic growth factors in the treatment of severe angina resulting from coronary artery disease. The company, which has obtained exclusive licenses to the technology from its co-developers, Indiana University and Columbia University, plans to use the growth factors in conjunction with transmyocardial revascularisation (TMR) technology. Cardiogenesis recently merged with Eclipse Surgical Technologies, whose TMR system has been recommended for approval by an FDA panel (see Clinica No 832, p 15).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT082744

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel